SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported):  September 4, 2003

 

CERUS CORPORATION

(Exact name of registrant as specified in its charter)

 

Delaware

 

0-21937

 

68-0262011

(State of jurisdiction)

 

(Commission File No.)

 

(IRS Employer Identification No.)

 

 

 

 

 

2411 Stanwell Drive
Concord, California 94520

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (925) 288-6000

 

 



 

Item 5.  Other Events.

 

On September 4, 2003, Cerus Corporation (the “Company”) and subsidiaries of Baxter International Inc. announced they are voluntarily halting Phase III trials for their pathogen-inactivated red blood cell program.  A copy of the Company’s press release is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

 

Item 7.           Exhibits.

 

Exhibit
Number

 

Description of Exhibit

99.1

 

Press Release, dated September 4, 2003, entitled “Baxter and Cerus halt red blood cell clinical trials for investigational pathogen inactivation system.”

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CERUS CORPORATION

 

 

 

 

 

 

 

 

Dated:   September 4, 2003

By:

/s/ Gregory W. Schafer

 

 

 

 

Gregory W. Schafer

 

 

 

Vice President, Finance and

 

 

 

Chief Financial Officer

 

3



 

Index to Exhibits

 

Exhibit
Number

 

Description of Exhibit

99.1

 

Press Release, dated September 4, 2003, entitled “Baxter and Cerus halt red blood cell clinical trials for investigational pathogen inactivation system.”

 

4